



VIJAYA DIAGNOSTIC CENTRE

May 26, 2022

To,
Listing Department
National Stock Exchange of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Company Code No. VIJAYA

To,
The Corporate Relations Department
BSE Limited,
Phiroz Jeejeebhoy Towers,
25th Floor, Dalal Street
Mumbai- 400 001
Company Code No. 543350

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on May 26, 2022.

We hereby inform you that the Board of Directors of the Company at their meeting held today has, inter-alia approved the following items of business.

1. Audited Standalone and Consolidated financial statements of the Company for the financial year ended March 31, 2022.
2. Recommended final dividend of 100% i.e. Re 1/- per equity share of face value of Re. 1/- each, for the Financial year ended March 31, 2022 and the said Dividend, if approved and declared by the shareholders at the forthcoming Annual General Meeting (AGM), will be paid within 30 days from the date of the AGM. The date of AGM and record date for the purpose of AGM and Dividend will be intimated in due course.

We are enclosing herewith the following;

- i. Audited Standalone and Consolidated financial results of the Company together with Statutory Auditor's Report on such financial results, for the financial year ended March 31, 2022.
- ii. Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015.

The meeting of the Board of Directors of the Company commenced at 7.25 p.m. and concluded at 8.55 p.m.

Please take the information on record.

Thanking you,

Yours faithfully,

For Vijaya Diagnostic Centre Limited

Anusha Kanumuru
Company Secretary





**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

CIN: U85195TG2002PLC039075

Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India

Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India

Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2022

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended	
		31 March 2022	31 December 2021	31 March 2021	31 March 2022	31 March 2021
		Audited Refer Note 4	Unaudited	Unaudited Refer Note 2	Audited	Audited
1	Income					
	(a) Revenue from operations	11,374.05	10,830.96	10,950.13	45,087.93	36,731.59
	(b) Other income	331.16	319.59	345.79	1,291.71	1,083.12
	Total income	11,705.21	11,150.55	11,295.92	46,379.64	37,814.71
2	Expenses					
	(a) Cost of materials consumed	1,747.12	1,572.40	1,580.29	6,895.21	5,551.05
	(b) Employee benefits expense	1,870.96	1,771.86	1,474.91	6,867.66	5,570.53
	(c) Finance costs	430.17	414.05	335.45	1,625.56	1,481.23
	(d) Depreciation and amortisation expense	1,514.46	1,286.77	1,236.64	5,213.65	4,972.96
	(e) Other expenses	3,049.64	2,767.61	2,509.40	11,339.48	9,280.32
	Total expenses	8,612.35	7,812.69	7,136.69	31,941.56	26,856.09
3	Profit before tax [1-2]	3,092.86	3,337.86	4,159.23	14,438.08	10,958.62
4	Tax expense					
	(a) Current tax	836.00	872.00	1,100.00	3,902.00	3,150.00
	(b) Deferred tax	(68.71)	(37.40)	(2.92)	(253.00)	(450.00)
	(c) Tax pertaining to earlier years	(21.39)	-	(23.53)	(21.39)	(23.53)
	Total tax expense	745.90	834.60	1,073.55	3,627.61	2,676.47
5	Profit for the year [3 - 4]	2,346.96	2,503.26	3,085.68	10,810.47	8,282.15
6	Other comprehensive income					
	<i>Items that will not be reclassified to profit or loss</i>					
	(a) Remeasurement of defined benefit obligations	33.18	(2.55)	9.70	25.53	4.66
	(b) Income-tax relating to above item	(8.35)	0.64	(2.44)	(6.43)	(1.17)
	Other comprehensive income for the year (net of tax)	24.83	(1.91)	7.26	19.10	3.49
7	Total comprehensive income for the period [5 + 6]	2,371.79	2,501.35	3,092.94	10,829.57	8,285.64
8	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6)	1,019.66	1,019.66	453.19	1,019.66	453.19
9	Other equity				45,978.38	35,601.72
10	Earnings per equity share (face value of Rs. 1 each, fully paid) (non annualized for quarter and year ended) (Refer Note 6)					
	- Basic (in Rs.)	2.30	2.45	3.03	10.60	8.12
	- Diluted (in Rs.)	2.29	2.44	3.02	10.54	8.12

Notes:

1. The above standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. The Company has completed its Initial Public Offer (IPO) and listed its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') on 14 September 2021. Accordingly, the figures for the quarter ended 31 March 2021 as reported in these financial results were neither reviewed nor subject to audit. However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs. The historical annual financial statements of the Company are available on the website of the Company at www.vijayadiagnostic.com
3. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 26 May 2022. The statutory auditors have expressed an unmodified audit opinion on these results.
4. The standalone figures for the quarter ended 31 March 2022 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the date of third quarter of the current financial year.
5. The Company's operations fall within a single business segment "Diagnostic services".
6. On 22 March 2021, the equity shares of the Company having the face value of Rs. 10 each were subdivided into 10 equity shares having a face value of Re. 1 each. Accordingly, 4,531,819 equity shares of face value of Rs. 10 each were subdivided into 45,318,190 equity shares of face value of Re. 1 each. The Company issued bonus shares on 27 May 2021 in proportion of five new equity shares of Re. 1 each for every four existing equity shares of Re. 1 each, resulting in total fully paid-up equity shares of 101,965,926 of Re. 1 each. The basic / diluted earnings per share have been adjusted towards this subdivision and bonus issue of shares for all the periods presented.
7. The Board of Directors at its meeting held on 26 May 2022, has proposed a final dividend of Re. 1 per equity share of Re. 1 each.
8. The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact on the financial results. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.
9. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com
10. Previous period figures have been regrouped / rearranged wherever considered necessary.

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
(Formerly known as 'Vijaya Diagnostic Centre Private Limited')
SURA
SURENDRAN
ATH REDDY
Dr. S. Surendranath Reddy
Executive Chairman
DIN Number: 00108599

Place: Hyderabad
Date: May 26, 2022

Standalone Balance Sheet			
(Rs. in Lakhs except as stated)			
Sl. No.	Particulars	As at 31 March 2022 Audited	As at 31 March 2021 Audited
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	18,410.71	13,396.83
	(b) Capital work-in-progress	3,410.10	818.21
	(c) Right of use assets	16,715.25	12,600.07
	(d) Investment properties	1,110.57	-
	(e) Other intangible assets	135.03	60.05
	(f) Intangible assets under development	6.84	123.63
	(g) Financial assets		
	(i) Investments	487.35	487.35
	(ii) Loans	575.00	-
	(iii) Other financial assets	740.86	1,203.67
	(h) Deferred tax assets (net)	826.98	580.41
	(i) Non-current tax assets (net)	3.73	24.26
	(j) Other non-current assets	2,227.81	610.95
	Total non-current assets	44,650.23	29,905.43
II	Current assets		
	(a) Inventories	409.99	249.79
	(b) Financial assets		
	(i) Investments	5,423.55	2,762.73
	(ii) Trade receivables	948.67	663.67
	(iii) Cash and cash equivalents	1,039.02	631.32
	(iv) Bank balances other than (iii) above	17,566.48	18,223.50
	(v) Loans	104.97	104.97
	(vi) Other financial assets	535.12	509.91
	(c) Other current assets	405.14	264.01
	Total current assets	26,432.94	23,409.90
	TOTAL ASSETS (I + II)	71,083.17	53,315.33
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	1,019.66	453.19
	(b) Other Equity	45,978.38	35,601.72
	Total equity	46,998.04	36,054.91
	Liabilities		
II	Non-current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	17,025.97	12,647.22
	(ii) Other financial liabilities	-	21.79
	(b) Provisions	712.04	705.09
	(c) Other non-current liabilities	11.65	5.30
	Total non-current liabilities	17,749.66	13,379.40
III	Current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	1,256.83	1,010.24
	(ii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	13.39	26.83
	Total outstanding dues of creditors other than micro enterprises and small enterprises	2,023.67	2,000.43
	(iii) Other financial liabilities	2,451.38	418.78
	(b) Provisions	154.65	58.58
	(c) Current tax liabilities (net)	89.66	146.84
	(d) Other current liabilities	343.69	219.32
	Total current liabilities	6,335.47	3,881.02
	Total liabilities (II + III)	24,085.13	17,260.42
	TOTAL EQUITY AND LIABILITIES (I + II + III)	71,083.17	53,315.33
<p>for and on behalf of the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')</p> <p>SURA SURENDRANA TH REDDY Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599</p> <p>Place: Hyderabad Date: May 26, 2022</p>			

Standalone Statement of Cashflows		(Rs. in Lakhs except as stated)	
Sl. No.	Particulars	Year ended 31 March 2022 (Audited)	Year ended 31 March 2021 (Audited)
A	Cash flow from operating activities		
	Profit before tax	14,438.08	10,958.62
	<i>Adjustments for:</i>		
	Depreciation and amortisation expense	5,213.65	4,972.96
	Net (gain)/loss on sale/ retirement of property, plant and equipment	(40.42)	(15.63)
	Interest income	(990.24)	(917.89)
	Profit on sale of mutual fund investments	(47.62)	(15.68)
	Provision for credit impaired receivables	-	27.93
	Provision for doubtful advances	43.63	-
	Employee stock option expense	113.56	19.55
	Fair value movement on financial instruments	(136.25)	(32.87)
	Finance costs	1,470.56	1,312.66
	Liability no longer required written back	(21.35)	(95.94)
	Operating profit before changes in assets and liabilities	20,043.60	16,213.71
	<i>Working Capital adjustments:</i>		
	(Increase) / Decrease in trade receivables	(293.55)	185.11
	(Increase)/Decrease in inventories	(160.20)	19.43
	(Increase) in other financial assets	(288.09)	(8.52)
	(Increase)/Decrease in other assets and deposits	(564.11)	(270.64)
	Decrease in trade payables	33.38	226.32
	Decrease/(Increase) in provisions and other liabilities	181.81	(29.38)
	Decrease/(Increase) in other financial liabilities	515.56	(435.11)
	Cash generated from operations	19,468.40	15,900.92
	Income tax paid, net	(3,917.26)	(3,117.09)
	Net cash generated from operating activities	15,551.14	12,783.83
B	Cash flows from investing activities		
	Acquisition of property, plant and equipment, Capital work-in-progress (CWIP), Other Intangible assets and Intangible assets under development (including capital advances and capital creditors)	(12,209.93)	(3,194.93)
	Proceeds from sale of property, plant and equipment	141.39	90.44
	Redemption of debt oriented liquid mutual funds, net	(2,476.94)	2,626.06
	Fixed deposits placed having original maturity of more than 3 months, net	1,243.94	(12,993.15)
	(Investment)/redemption of margin money deposits, net	(2.01)	(0.36)
	Loans given to subsidiaries	(725.00)	147.44
	Loans repaid from subsidiaries	150.00	-
	Interest received	1,206.78	442.17
	Net cash (used) from investing activities	(12,671.77)	(12,882.33)
C	Cash flows from financing activities		
	Repayment of long-term borrowings	-	(2,790.00)
	Repayment of lease liabilities	(2,471.67)	(1,896.53)
	Interest paid	-	(132.18)
	Net cash (used) from financing activities	(2,471.67)	(4,818.71)
	Net increase / (decrease) in cash and cash equivalents (A + B + C)	407.70	(4,917.21)
	Cash and cash equivalents at the beginning of the financial period	631.32	5,548.53
	Cash and cash equivalents at end of the period	1,039.02	631.32
Cash and cash equivalents as per above comprise of the following:			
		As At March 31, 2022	As At March 31, 2021
	Cash on hand	53.58	79.76
	Balances with banks		
	- in current accounts	985.44	551.56
	- in deposit accounts having maturity less than three months	-	-
	Total cash and cash equivalents	1,039.02	631.32
<p>for and on behalf of the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') SURA SURENDRANA TH REDDY Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599</p>			
Place: Hyderabad Date: May 26, 2022			

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Independent Auditor's Report

To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') (hereinafter referred to as the "Company") for the year ended 31 March 2022, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Attention is drawn to the fact that the figures for the quarter ended 31 March 2021, as reported in these standalone annual financial results have been approved by the Company's Board of Directors, but have not been subjected to audit since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company during the quarter ended 30 September 2021.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records

Registered Office:

B S R & Associates (a partnership firm with Registration No. BA69226) converted into B S R & Associates LLP (a Limited Liability Partnership with LLP Registration No. AAB-8182) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter(s)

- a. The standalone annual financial results include the results for the quarter ended 31 March 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Associates LLP

Chartered Accountants

Firm's Registration No.:116231WW-100024

**AMIT
KUMAR
BAJAJ**

Digitally signed
by AMIT KUMAR
BAJAJ
Date: 2022.05.26
20:26:55 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad

26 May 2022

Membership No.: 218685

UDIN:22218685AJQLET6618



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')
CIN: U85195TG2002PLC039075

Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India

Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India

Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Audited Consolidated Financial Results for the quarter and year ended 31 March 2022

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended	
		31 March 2022	31 December 2021	31 March 2021	31 March 2022	31 March 2021
		Audited Refer Note 4	Unaudited	Unaudited Refer Note 2	Audited	Audited
1	Income					
	(a) Revenue from operations	11,620.03	11,077.58	11,200.82	46,236.99	37,674.57
	(b) Other income	319.09	320.15	420.78	1,283.06	1,184.64
	Total income	11,939.12	11,397.73	11,621.60	47,520.05	38,859.21
2	Expenses					
	(a) Cost of materials consumed	1,787.76	1,629.89	1,626.48	7,149.91	5,709.45
	(b) Employee benefits expense	1,919.74	1,822.15	1,517.44	7,065.94	5,743.33
	(c) Finance costs	433.51	417.58	346.91	1,645.03	1,524.60
	(d) Depreciation and amortisation expense	1,528.06	1,300.72	1,254.92	5,268.61	5,045.14
	(e) Other expenses	3,126.88	2,842.57	2,615.16	11,652.13	9,624.30
	Total expenses	8,795.95	8,012.91	7,360.91	32,781.62	27,646.82
3	Profit before tax [1 - 2]	3,143.17	3,384.82	4,260.69	14,738.43	11,212.39
4	Tax expense					
	(a) Current tax	842.13	881.51	1,122.07	3,963.56	3,174.49
	(b) Deferred tax, net	(76.02)	(45.26)	(6.09)	(283.06)	(453.17)
	(c) Tax pertaining earlier years	(11.30)	2.47	(23.53)	(8.83)	(21.58)
	Total tax expense	754.81	838.72	1,092.45	3,671.67	2,699.74
5	Profit for the year [3-4]	2,388.36	2,546.10	3,168.24	11,066.76	8,512.65
6	Other comprehensive income					
	<i>Items that will not be reclassified to profit or loss</i>					
	(a) Remeasurement of the defined benefit obligations	35.93	(2.77)	4.88	27.62	(0.16)
	(b) Income-tax relating to above item	(8.88)	0.64	(2.44)	(6.96)	(1.17)
	Other comprehensive income for the year (net of tax)	27.05	(2.13)	2.44	20.66	(1.33)
7	Total comprehensive income for the year [5+6]	2,415.41	2,543.97	3,170.68	11,087.42	8,511.32
	Profit for the period attributable to:					
	Owners of the Company	2,371.25	2,528.65	3,141.62	10,968.06	8,447.82
	Non controlling interests	17.11	17.45	26.62	98.70	64.83
	Other comprehensive income attributable to:					
	Owners of the Company	26.21	(2.05)	4.26	20.07	0.49
	Non controlling interests	0.84	(0.08)	(1.82)	0.59	(1.82)
	Total comprehensive income attributable to:					
	Owners of the Company	2,397.46	2,526.60	3,145.88	10,988.13	8,448.31
	Non controlling interests	17.95	17.37	24.80	99.29	63.01
8	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6)	1,019.66	1,019.66	453.19	1,019.66	453.19
9	Other equity				45,802.27	35,447.45
10	Earnings per equity share (face value of Re. 1 each fully paid up) (non annualized for quarter and year ended) (Refer Note 6)					
	Basic (in Rs.)	2.33	2.48	3.08	10.76	8.28
	- Diluted (in Rs.)	2.31	2.46	3.08	10.69	8.28

Notes:

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited (formerly known as 'Vijaya Diagnostic Centre Private Limited') ('the Company') and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. The Company has completed its Initial Public Offer ('IPO') and listed its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') on 14 September 2021. Accordingly, the figures for the quarter ended 31 March 2021 as reported in these financial results were neither reviewed nor subject to audit. However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Group's affairs. The historical annual financial statements of the Company and its subsidiaries are available in the website of the Company at www.vijayadiagnostic.com.
3. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 26 May 2022. The statutory auditors have expressed an unmodified audit opinion on these results.
4. The consolidated figures for the quarter ended 31 March 2022 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the date of third quarter of the current financial year.
5. The Group's operations fall within a single business segment "Diagnostic services".
6. On 22 March 2021, the equity shares of the Company having the face value of Rs. 10 each were subdivided into 10 equity shares having a face value of Re. 1 each. Accordingly, 4,531,819 equity shares of face value of Rs. 10 each were subdivided into 45,318,190 equity shares of face value of Re. 1 each. The Company issued bonus shares on 27 May 2021 in proportion of five new equity shares of Re. 1 each for every four existing equity shares of Re. 1 each, resulting in total fully paid-up equity shares of 101,965,926 of Re. 1 each. The basic / diluted earnings per share have been adjusted towards this subdivision and bonus issue of shares for all the periods presented.
7. The Board of Directors at its meeting held on 26 May 2022, has proposed a final dividend of Re. 1 per equity share of Re. 1 each.
8. The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Group is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Group based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact on the financial results. Based on the current estimates, the Group expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Group will continue to closely monitor any material changes to future economic condition.
9. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com.
10. Previous period figures have been regrouped / rearranged wherever considered necessary.

Place: Hyderabad
Date: 26 May 2022

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
(Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURA
SURENDRAN
ATH REDDY

Dr. S. Surendranath Reddy
Executive Chairman
DIN Number: 00108599

Consolidated Balance sheet

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	As at 31 Mar 2022	As at 31 Mar 2021
		Audited	Audited
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	19,661.08	13,576.83
	(b) Capital work-in-progress	3,409.88	818.21
	(c) Right of use assets	16,715.25	12,600.07
	(d) Other intangible assets	135.68	60.05
	(e) Intangible assets under development	6.84	123.63
	(f) Goodwill on consolidation	533.75	533.75
	(g) Financial assets		
	(i) Investments	4.00	4.00
	(ii) Other financial assets	754.71	1,222.17
	(h) Deferred tax assets, (net)	885.81	609.71
	(i) Non-current tax assets, (net)	22.57	56.99
	(j) Other non-current assets	2,227.81	610.91
	Total non-current assets	44,357.38	30,216.32
II	Current assets		
	(a) Inventories	427.67	264.43
	(b) Financial assets		
	(i) Investments	5,423.55	2,762.73
	(ii) Trade receivables	977.09	670.45
	(iii) Cash and cash equivalents	1,104.99	668.56
	(iv) Bank balances other than (iii) above	18,130.69	18,755.50
	(v) Other financial assets	514.53	518.93
	(c) Other current assets	410.18	267.16
	Total current assets	26,988.70	23,907.76
	TOTAL ASSETS (I + II)	71,346.08	54,124.08
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	1,019.66	453.19
	(b) Other equity	45,802.27	35,447.45
	Equity attributable to owners of the Company	46,821.93	35,900.64
	Non-controlling interest	132.31	22.62
	Total equity	46,954.24	35,923.26
II	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	-	327.45
	(ii) Lease liabilities	17,025.97	12,647.22
	(iii) Other financial liabilities	-	21.79
	(b) Provisions	741.84	770.18
	(c) Other non-current liabilities	11.65	5.30
	Total non-current liabilities	17,779.46	13,771.94
III	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	63.46	119.69
	(ii) Lease liabilities	1,256.83	1,010.24
	(iii) Trade payables		
	Total outstanding dues of micro and small enterprises	16.76	26.83
	Total outstanding dues of creditors other than micro and small enterprises	2,147.11	2,189.36
	(iv) Other financial liabilities	2,480.30	612.57
	(b) Provisions	208.63	13.51
	(c) Current tax liabilities, net	90.30	162.40
	(d) Other current liabilities	348.99	234.22
	Total current liabilities	6,612.38	4,428.88
	Total liabilities (II + III)	24,391.84	18,200.82
	TOTAL EQUITY AND LIABILITIES (I + II + III)	71,346.08	54,124.08

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
 (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

SURA
 SURENDRAN
 ATH REDDY

Dr. S. Surendranath Reddy
 Executive Chairman
 DIN Number: 00108599

Place: Hyderabad
 Date: 26 May 2022

Digitally signed by SURA
 SURENDRANATH REDDY
 DN: cn=SURA SURENDRANATH REDDY, o=Vijaya Diagnostic Centre Limited, email=s.surendranath@vijayadiagnosticcentre.com, c=IN
 Date: 2022.05.26 10:57:30 +05'30'

Consolidated Statement of Cashflows		(Rs. in Lakhs except as stated)	
Sl.No	Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
		Audited	Audited
A.	Cash flow from operating activities		
	Profit before tax	14,738.43	11,212.39
	Adjustments for:		
	Depreciation and amortisation expense	5,268.61	5,045.14
	Net gain on sale/ retirement of property, plant and equipment	(39.79)	(15.63)
	Interest income	(979.86)	(959.57)
	Profit on sale of mutual fund investments	(47.62)	(15.68)
	Provision for credit impaired receivables	-	33.88
	Provision for doubtful advances	43.63	-
	Fair value movement on financial instruments	(136.25)	(32.87)
	Liabilities no longer required, written back	(21.35)	(154.36)
	Employee stock option expense	113.56	19.55
	Finance cost	1,521.49	1,350.85
	Bad debts written-off	-	33.16
	Advances written-off	-	25.85
	Operating profit before working capital changes	20,460.85	16,542.71
	Net changes in:		
	(Increase) / decrease in inventories	(163.24)	12.89
	(Increase)/ decrease in trade receivables	(306.64)	91.89
	(Increase) in other financial assets	(287.92)	(196.93)
	(Increase) in other assets and deposits	(551.05)	(83.97)
	(Decrease) / Increase in trade payables	(30.97)	46.74
	Increase / (Decrease) in provisions and other liabilities	174.90	(25.79)
	Increase / (Decrease) in other financial liabilities	496.35	(301.42)
	Cash generated from operations	19,792.28	16,086.12
	Income tax paid, net	(3,992.41)	(3,122.53)
	Net cash generated from operating activities	15,799.87	12,963.59
B.	Cash flows from investing activities		
	Acquisition of property, plant and equipment, Capital work-in-progress (CWIP), Other Intangible assets and Intangible assets under development (including capital advances and capital creditors)	(12,234.85)	(3,213.01)
	Proceeds from sale of property, plant and equipment	142.03	90.32
	Purchase of further stake from NCI in subsidiary	(170.00)	-
	(Invest)/Redemption of debt oriented liquid mutual funds, (net)	(2,476.94)	2,753.14
	Fixed deposits placed having original maturity of more than 3 months, (net)	1,207.81	(13,080.48)
	Interest received	1,225.72	475.10
	Net cash (used) from investing activities	(12,306.23)	(12,974.93)
C.	Cash flows from financing activities		
	Repayment of long-term borrowings	(327.45)	(2,826.01)
	Proceeds/(Repayments) from/to short-term borrowings, net	(56.23)	(10.76)
	Repayment of lease liabilities (including interest)	(2,471.67)	(1,896.53)
	Interest paid	(201.86)	(143.61)
	Net cash (used) from financing activities	(3,057.21)	(4,876.91)
	Net increase/(decrease) in cash and cash equivalents (A + B + C)	436.43	(4,888.25)
	Cash and cash equivalents at the beginning of the year	668.56	5,556.81
	Cash and cash equivalents at end of the year	1,104.99	668.56
Cash and cash equivalents as per above comprise of the following:			
		March 31, 2022	March 31, 2021
	Cash on hand	54.93	81.86
	Balances with banks		
	- in current accounts	1,035.80	586.70
	- in deposit accounts having maturity less than three months	14.26	-
	Total cash and cash equivalents	1,104.99	668.56
<p>for and on behalf of the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')</p> <p>SURA SURENDRAN ATH REDDY Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599</p> <p>Place: Hyderabad Date: 26 May 2022</p>			

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Independent Auditor's Report

To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2022, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Attention is drawn to the fact that the figures for the quarter ended 31 March 2021, as reported in these consolidated annual financial results have been approved by the Holding Company's Board of Directors, but have not been subjected to audit since the requirement of submission of quarterly consolidated financial results is applicable on listing of equity shares of the Company during the quarter ended 30 September 2021.

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate / consolidated audited financial statements of the subsidiaries, the aforesaid consolidated annual financial results:

a. include the annual financial results of the following entities:

1. Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')
(Parent)

Subsidiaries

2. Medinova Diagnostic Services Limited
3. VDC Diagnostics (Karnataka) LLP
4. Doctors Lab Medical Services Private Limited
5. Medinova Millenium MRI Services LLP
6. Namrata Diagnostic Centre Private Limited

b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors'/Designated Partners' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies / Designated Partners of limited liability partnerships (LLP) included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company / LLP and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies / Designated Partners of limited liability partnerships (LLP) included in the Group are responsible for assessing the ability of each company / LLP to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors / designated partners either intends to liquidate the company / LLP or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies / Designated Partners of the LLP included in the Group is responsible for overseeing the financial reporting process of each company / LLP.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matter(s)

- a The consolidated annual financial results include the audited financial results of five subsidiaries, whose financial statements reflect total assets (before consolidation adjustments) of Rs. 1,389.24 lakhs as at 31 March 2022, total revenue (before consolidation adjustments) of Rs. 1,321.09 lakhs and total net profit after tax (before consolidation adjustments) of Rs. 256.21 lakhs and net cash inflows (before consolidation adjustments) of Rs 28.73 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditor's reports on financial statements of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

with respect to our reliance on the work done and the reports of the other auditors.

- b. The consolidated annual financial results include the results for the quarter ended 31 March 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Associates LLP

Chartered Accountants

Firm's Registration No.: 116231W/W-100024

**AMIT KUMAR
BAJAJ**

Digitally signed by
AMIT KUMAR BAJAJ
Date: 2022.05.26
20:25:46 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad

26 May 2022

Membership No.: 218685

UDIN: 22218685AJQMBJ6411



**VIJAYA
DIAGNOSTIC
CENTRE**

DECLARATION

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015, we hereby declare that the Statutory Auditors of the Company, have issued Audit Reports with 'Unmodified Opinion' on the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2022.

For Vijaya Diagnostic Centre Limited

K. Anusha

**Anusha Kanumuru
Company Secretary**

